A phase III, randomized, open-label study to compare the efficacy of tislelizumab versus chemotherapy as second-line therapy for advanced unresectable/metastatic esophageal squamous cell carcinoma (ESCC)

L. Shea1, J. Ajani2, S-B. Kim3, E. Van Cutsem4, B. Guo5, J. Song6, V. Paton7, K. Kato8
1Gastrointestinal Oncology, Peking University Cancer Hospital & Institute, Beijing, China, 2MD Anderson Cancer Center, The University of Texas, Houston, TX, USA, 3Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea, 4Leuven Cancer Institute, University Hospitals Leuven, Leuven, Belgium, 5Medical Oncology, BeGene (Beijing) Co., Ltd, Beijing, China, 6Biometry, BeGene USA, Inc., Fort Lee, NJ, USA, 7Clinical Development, BeGene USA, Inc., Emeryville, CA, USA, 8Gastrointestinal Oncology Division, National Cancer Center Hospital, Tokyo, Japan

Background: Approximately 40% of patients (pts) with esophageal cancer are diagnosed with advanced unresectable or metastatic disease; the 5-year survival rate for advanced disease is < 5%. Inhibition of PD-1 has demonstrated antitumor activity and was generally well tolerated in pts with advanced unresectable or metastatic ESCC. Tislelizumab, a humanized IgG4 monoclonal antibody, has high affinity and specificity for PD-1. Tislelizumab was specifically engineered to minimize FcγR binding on macrophages that, based on preclinical evidence, is believed to minimize potentially negative interactions with other immune cells. A first-in-human study (NCT02407990) demonstrated that single-agent tislelizumab was generally well tolerated and had preliminary antitumor effects in pts with solid tumors, including ESCC. A recommended phase 3 dose of 200 mg administered IV every 3 weeks (Q3W) has been established for tislelizumab.

Trial design: This phase 3, randomized study (NCT03430843) was designed to evaluate the efficacy, safety, and tolerability of tislelizumab compared with chemotherapy for second-line treatment of advanced unresectable/metastatic ESCC. Adult pts, aged ≥18 years, with histologically or cytologically confirmed ESCC that has progressed with first-line therapy, have ≥1 measurable/evaluable lesion, and have an Eastern Cooperative Oncology score ≤1 will be enrolled. Approximately 450 pts will be randomized (1:1) to receive either tislelizumab 200 mg IV Q3W or investigator-chosen chemotherapy (paclitaxel 135–175 mg/m² IV Q3W or 100 mg/m² IV weekly for 6 weeks with 1 week of rest [Japan only], docetaxel 75 mg/m² or 70 mg/m² IV Q3W, or irinotecan 125 mg/m² IV Q3W). Overall survival is the primary endpoint; secondary endpoints include objective response rate, progression free survival, duration of response, and health-related quality-of-life outcomes. Safety/tolerability will be assessed by monitoring adverse events (AEs), including immune-related AEs, as well as physical examinations, vital signs, and electrocardiograms. As of 11 April 2018, 6 patients have been enrolled.

Clinical trial identification: NCT03430843.

Editorial acknowledgement: Medical writing and editorial assistance was provided by Regina Switzer, PhD (SuccinctChoice Medical Communications, Chicago, IL).

Legal entity responsible for the study: BeGene, Ltd.

Funding: BeGene, Ltd.